"Integrum has left a transformative phase and is now entering a phase with full focus on execution and growth," says Martin Hillsten in the interview.
In the conversation, he also discusses the shift toward a more data-driven commercial model, the launch of the digital patient portal in the US, and the Afyri initiative – an effort to accelerate the development of intelligent bionics.